KDOQI对美国KDIGO 2021肾小球疾病管理临床实践指南的解读
KDOQI工作组对KDIGO 2021肾小球疾病管理指南进行逐章解读,针对美国实施提出意见。原文指出自2012年首版以来分子理解加速、新型免疫抑制与靶向治疗涌现,但争议领域仍多,且KDIGO 2021发布后已有新进展未纳入。
要点
- KDIGO 2021指南是2012年首版以来对肾小球疾病管理的首次更新。
- 分子理解加速及新型免疫抑制与靶向治疗出现使更新成为必要。
- KDOQI解读逐章提供针对美国实施KDIGO 2021指南的意见。
核心结论
- KDOQI工作组生成逐章伴随意见文章,提供针对美国实施KDIGO 2021指南的解读。
- 尽管有更新,许多争议领域仍存在,且KDIGO 2021发布后的进一步更新未被该指南涵盖。
研究设计与样本
- KDOQI工作组对KDIGO 2021肾小球疾病管理临床实践指南编写的逐章解读意见文章。
局限性
- 原文指出许多争议领域仍存在。
- 原文指出KDIGO 2021发布后的进一步更新未被该指南涵盖。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases represents the first update to this set of recommendations since the initial set of KDIGO guideline recommendations was published in 2012. The pace of growth in our molecular understanding of glomerular disease has quickened and a number of newer immunosuppressive and targeted therapies have been introduced since the original set of guideline recommendations, making such an update necessary. Despite these updates, many areas of controversy remain. In addition, further updates since the publication of KDIGO 2021 have occurred which this guideline does not encompass. With this commentary, the KDOQI work group has generated a chapter-by-chapter companion opinion article that provides commentary specific to the implementation of the KDIGO 2021 guideline in the United States.
引用
- Beck LH, Ayoub I, Caster D, et al. KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases. Am J Kidney Dis. 2023. PMID: 37341661. doi:10.1053/j.ajkd.2023.02.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。